Epidemiology of SARS-CoV-2 in Low-income Countries.
低收入国家 SARS-CoV-2 的流行病学。
基本信息
- 批准号:10188735
- 负责人:
- 金额:$ 63.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-07-01 至 2021-06-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcquired Immunodeficiency SyndromeAddressAdultAfricanAntibodiesAreaArrhythmiaAutopsyCOVID-19COVID-19 pandemicCardiacCaringCellular PhoneCessation of lifeChronic lung diseaseClinicalClinical TrialsCohort AnalysisCollaborationsCommunicationCommunitiesConduct Clinical TrialsCountryDataDevelopmentDiseaseEchocardiographyElectrocardiogramEmergency SituationEnrollmentEpidemicEpidemiologyFunctional disorderFundingFutureGeographyGoalsHIVHIV InfectionsHIV/TBHaitiHaitianHealthHeart DiseasesHeart InjuriesHome environmentHospital RecordsHypertensionImmunoglobulin GIncidenceIncomeInfectionInfrastructureIntervention TrialLeftLeft Ventricular FunctionLow incomeMotionMyocardial IschemiaMyocarditisNational Institute of Allergy and Infectious DiseaseNatural HistoryOutcomeParticipantPatientsPopulationPositioning AttributePrevalencePreventionPreventive InterventionProceduresProtocols documentationPulmonary HypertensionPulmonary TuberculosisReport (document)ReportingResearchResearch InfrastructureRiskRisk FactorsSeminalSerologic testsSeveritiesSurvivorsSymptomsTanzaniaTelephoneTelephone InterviewsTroponinUnited States National Institutes of HealthUniversitiesVentricularViral Respiratory Tract InfectionVirus DiseasesVisitWorld Health Organizationcohortfallsfollow-upheart functionimprovedinfection ratelow income countrymortalitypandemic diseasepublic health interventionsymptomatology
项目摘要
The COVID-19 pandemic has now spread from high- and middle-income countries to low-income countries,
including Haiti and Tanzania. The natural history of COVID-19 is unknown in low-income countries. We
propose to study a combined cohort of 3,054 adults in Haiti and Tanzania to determine the attack rate of
SARS-CoV-2 infection and severe COVID-19, to examine interactions with HIV infection, pulmonary
tuberculosis, and hypertension in populations of African descent, and to determine long term cardiac
complications of COVID-19. Cornell University has collaborated with the Groupe Haitien d’Etude du Sarcome
de Kaposi et des Infections Opportunistes (GHESKIO) in Haiti for 38 years and for 15 years with the Mwanza
Intervention Trials Unit (MITU) in Tanzania. The proposed emergency supplement leverages these
collaborations and four established NIH-supported cohorts, which have already been enrolled, to address
NIAID priority areas. The specific aims are:
1.To determine the incidence proportion of SARS-CoV-2 infection and the attack rate and risk factors
for severe COVID-19, in well characterized cohorts of 3,054 adults from low-income communities in
Haiti and Tanzania. Starting May 1, 2020 we will conduct monthly telephone interviews with the 3,054
participants who are in active follow-up to record symptoms of COVID-19 during the pandemic. Participants will
also be encouraged to telephone us if they develop new symptoms. We have cell phone numbers for all
cohort participants and have established procedures for telephone communication. We will also review hospital
records, perform verbal autopsies, and grade severity of COVID-19. We have banked sera from all participants
collected in 2016-2019. In September-November 2020 and again in March-May 2021, we will collect follow-up
sera and perform serologic testing for the presence of anti-SARS-CoV-2 IgG antibodies. We will determine the
odds for development of severe COVID-19 in participants who had HIV, TB, and hypertension.
2. To determine the cardiac complications of SARS-CoV-2 infection in 1,909 adults with known baseline
cardiac function. In 1,909 patients who previously had baseline EKGs and echocardiograms (2016-2019), we
will repeat cardiac echo and EKG in 2021 to quantify the odds for development of incident left ventricular
systolic dysfunction in those who did and did not become SARS-CoV-2 infected. LV function will be quantified
by global longitudinal strain. We will also determine incidence of right ventricular systolic dysfunction,
pulmonary hypertension and segmental wall motion abnormalities by echocardiogram, and new Q-waves and
other abnormalities on EKG.
Defining viral infection rates and natural history in low-income countries will be critical for future prevention
interventions. Determining risk for people with HIV, TB, and hypertension will improve their care and
prevention. Understanding cardiac sequelae of SARS-CoV-2 will improve care for COVID-19 survivors.
COVID-19大流行现已从高收入和中等收入国家蔓延至低收入国家,
包括海地和坦桑尼亚。在低收入国家,COVID-19 的自然史尚不清楚。我们
建议对海地和坦桑尼亚的 3,054 名成年人进行联合队列研究,以确定以下疾病的发病率:
SARS-CoV-2 感染和严重的 COVID-19,以检查与 HIV 感染、肺部感染的相互作用
非洲裔人群中的结核病和高血压,并确定长期心脏病
COVID-19 的并发症。康奈尔大学与 Groupe Haitien d’Etude du Sarcome 合作
de Kaposi et des Infections Opportunistes (GHESKIO) 在海地工作了 38 年,并在姆万扎工作了 15 年
坦桑尼亚干预试验组(MITU)。拟议的紧急补充利用了这些
合作和四个已建立的 NIH 支持的队列,这些队列已经注册,以解决
NIAID 优先领域。具体目标是:
1.确定SARS-CoV-2感染的发病比例以及发病率和危险因素
针对严重的 COVID-19,在来自低收入社区的 3,054 名成年人组成的特征明确的队列中
海地和坦桑尼亚。从 2020 年 5 月 1 日开始,我们将每月对 3,054 名
在大流行期间积极跟踪记录 COVID-19 症状的参与者。参与者将
如果他们出现新症状,也鼓励给我们打电话。我们有所有人的手机号码
队列参与者并已建立电话通讯程序。我们也会检查医院
记录、进行口头尸检并对 COVID-19 的严重程度进行分级。我们已储存所有参与者的血清
2016-2019年收集。 2020年9月至11月以及2021年3月至5月,我们将收集后续信息
血清并对是否存在抗 SARS-CoV-2 IgG 抗体进行血清学检测。我们将确定
患有 HIV、结核病和高血压的参与者罹患重症 COVID-19 的几率。
2. 确定 1,909 名基线已知的成年人感染 SARS-CoV-2 后的心脏并发症
心脏功能。在 1,909 名之前接受过基线心电图和超声心动图检查(2016-2019 年)的患者中,我们
将在 2021 年重复心脏超声和心电图,以量化发生左心室事件的几率
感染和未感染 SARS-CoV-2 的人的收缩功能障碍。 LV 功能将被量化
通过全局纵向应变。我们还将确定右心室收缩功能障碍的发生率,
超声心动图显示肺动脉高压和节段性室壁运动异常,以及新的 Q 波和
心电图的其他异常。
确定低收入国家的病毒感染率和自然史对于未来的预防至关重要
干预措施。确定艾滋病毒、结核病和高血压患者的风险将改善他们的护理和治疗
预防。了解 SARS-CoV-2 的心脏后遗症将改善对 COVID-19 幸存者的护理。
项目成果
期刊论文数量(69)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of C-2 substitution on the stability of non-traditional cephalosporins in mouse plasma.
C-2取代对非传统头孢菌素在小鼠血浆中稳定性的影响。
- DOI:10.1038/s41429-019-0167-y
- 发表时间:2019
- 期刊:
- 影响因子:0
- 作者:Zimmerman,Matthew;McDonald,StaceyL;Ho-Liang,Hsin-Pin;Porubsky,Patrick;Nguyen,Quyen;Pharr,CameronW;Perkowski,AndrewJ;Smith,Robert;Schoenen,FrankJ;Gold,BenS;Zhang,David;Nathan,CarlF;Dartois,Véronique;Aubé,Jeffrey
- 通讯作者:Aubé,Jeffrey
Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.
- DOI:10.1021/acsinfecdis.6b00172
- 发表时间:2017-02-10
- 期刊:
- 影响因子:5.3
- 作者:Totaro KA;Barthelme D;Simpson PT;Jiang X;Lin G;Nathan CF;Sauer RT;Sello JK
- 通讯作者:Sello JK
Rapid Emergence and Spread of Severe Acute Respiratory Syndrome Coronavirus 2 Gamma (P.1) Variant in Haiti.
海地中严重急性呼吸综合征2伽马病毒(第1页)的快速出现和扩散。
- DOI:10.1093/cid/ciab736
- 发表时间:2022-06-10
- 期刊:
- 影响因子:0
- 作者:Tagliamonte MS;Mavian C;Zainabadi K;Cash MN;Lednicky JA;Magalis BR;Riva A;Deschamps MM;Liautaud B;Rouzier V;Fitzgerald DW;Pape JW;Morris JG;Salemi M
- 通讯作者:Salemi M
Impaired IL-23-dependent induction of IFN-γ underlies mycobacterial disease in patients with inherited TYK2 deficiency.
- DOI:10.1084/jem.20220094
- 发表时间:2022-10-03
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Identification of β-Lactams Active against Mycobacterium tuberculosis by a Consortium of Pharmaceutical Companies and Academic Institutions.
由制药公司和学术机构的财团鉴定β-内酰胺对结核分枝杆菌的识别。
- DOI:10.1021/acsinfecdis.1c00570
- 发表时间:2022-03-11
- 期刊:
- 影响因子:5.3
- 作者:Gold B;Zhang J;Quezada LL;Roberts J;Ling Y;Wood M;Shinwari W;Goullieux L;Roubert C;Fraisse L;Bacqué E;Lagrange S;Filoche-Rommé B;Vieth M;Hipskind PA;Jungheim LN;Aubé J;Scarry SM;McDonald SL;Li K;Perkowski A;Nguyen Q;Dartois V;Zimmerman M;Olsen DB;Young K;Bonnett S;Joerss D;Parish T;Boshoff HI;Arora K;Barry CE 3rd;Guijarro L;Anca S;Rullas J;Rodríguez-Salguero B;Martínez-Martínez MS;Porras-De Francisco E;Cacho M;Barros-Aguirre D;Smith P;Berthel SJ;Nathan C;Bates RH
- 通讯作者:Bates RH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael Stephen Glickman其他文献
Michael Stephen Glickman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael Stephen Glickman', 18)}}的其他基金
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
Rip1 控制结核分枝杆菌的应激抵抗力和毒力
- 批准号:
10547809 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
Rip1 控制结核分枝杆菌的应激抵抗力和毒力
- 批准号:
10338102 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
Rip1 controlled stress resistance and virulence in Mycobacterium tuberculosis
Rip1 控制结核分枝杆菌的应激抵抗力和毒力
- 批准号:
10084263 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
RP-4:膀胱癌 BCG 免疫治疗的免疫预测因子
- 批准号:
10226974 - 财政年份:2018
- 资助金额:
$ 63.29万 - 项目类别:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
RP-4:膀胱癌 BCG 免疫治疗的免疫预测因子
- 批准号:
10453636 - 财政年份:2018
- 资助金额:
$ 63.29万 - 项目类别:
RP-4: Immunologic Predictors of BCG Immunotherapy for Bladder Cancer
RP-4:膀胱癌 BCG 免疫治疗的免疫预测因子
- 批准号:
9979823 - 财政年份:2018
- 资助金额:
$ 63.29万 - 项目类别:
Tri-Institutional TB Research Unit: Persistence and Latency
三机构结核病研究小组:持续性和潜伏期
- 批准号:
8691646 - 财政年份:2014
- 资助金额:
$ 63.29万 - 项目类别:
Tri-Institutional TB Research Unit: Persistence and Latency
三机构结核病研究单位:持续性和潜伏期
- 批准号:
9753887 - 财政年份:2014
- 资助金额:
$ 63.29万 - 项目类别:
Tri-Institutional TB Research Unit: Persistence and Latency
三机构结核病研究单位:持续性和潜伏期
- 批准号:
9081457 - 财政年份:2014
- 资助金额:
$ 63.29万 - 项目类别:
相似海外基金
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
10219039 - 财政年份:2020
- 资助金额:
$ 63.29万 - 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9981476 - 财政年份:2019
- 资助金额:
$ 63.29万 - 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
- 批准号:
9364184 - 财政年份:2016
- 资助金额:
$ 63.29万 - 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
- 批准号:
236932 - 财政年份:2011
- 资助金额:
$ 63.29万 - 项目类别:
Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554155 - 财政年份:1991
- 资助金额:
$ 63.29万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
- 批准号:
3554156 - 财政年份:1991
- 资助金额:
$ 63.29万 - 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
- 批准号:
2063342 - 财政年份:1991
- 资助金额:
$ 63.29万 - 项目类别:














{{item.name}}会员




